Exact Mass: 337.27474100000006
Exact Mass Matches: 337.27474100000006
Found 134 metabolites which its exact mass value is equals to given mass value 337.27474100000006,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dodeca-3,6,9-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-3,6,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,6,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,6,9-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,6,9-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-2,5,8-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-2,5,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-2,5,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-2,5,8-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-2,5,8-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
(4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,10E)-dodeca-4,6,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,6,8-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-4,6,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,6,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,6,8-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,6,8-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,7,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-4,7,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,7,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,7,10-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,7,10-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-2,4,6-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-2,4,6-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-2,4,6-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-3,5,7-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,5,7-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,5,7-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-6,8,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-6,8,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,8,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,8,10-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,8,10-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,7,9-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-5,7,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,7,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,7,9-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,7,9-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Linoleoyl Glycine
C20H35NO3 (337.26168000000007)
N-linoleoyl glycine, also known as 15-methylpalmitate or C17ISO belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Linoleic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Linoleoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Linoleoyl Glycine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Lauroyl Histidine
C18H31N3O3 (337.23652960000004)
N-lauroyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
suloctidil
C20H35NOS (337.24392200000005)
Pafenolol
C18H31N3O3 (337.23652960000004)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
1-methyl-2-(4z,7z)-4,7-tridecadienyl-4(1h)-quinolinone
(11E)-2-acetamido-3-acetoxyhexadeca-11,15-diene|diacetyl obscuraminol C
C20H35NO3 (337.26168000000007)
(16aR)-8-Formyl-13t-((S)-1-hydroxy-propyl)-(16ar)-1,4,5,6,7,8,9,10,11,13,16,16a-dodecahydro-3H-pyrido[2,1-d][1,5,9]triazacyclotridecin-2-on|(16aR)-8-formyl-13t-((S)-1-hydroxy-propyl)-(16ar)-1,4,5,6,7,8,9,10,11,13,16,16a-dodecahydro-3H-pyrido[2,1-d][1,5,9]triazacyclotridecin-2-one|8-formyl-4-(1-hydroxy-propyl)-1,4,6,7,8,9,10,11,12,13,15,15a-dodecahydro-5H-4a,8,13-triaza-benzocyclotridecen-14-one|Palustridin|Palustridine
C18H31N3O3 (337.23652960000004)
(7Z)-2-acetamido-3-acetoxyhexadeca-7,15-diene|diacetyl obscuraminol B
C20H35NO3 (337.26168000000007)
suloctidil
C20H35NOS (337.24392200000005)
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
N-cis-hexadec-9Z-enoyl-L-Homoserine lactone
C20H35NO3 (337.26168000000007)
1-Methyl-2-(4Z,7Z)-4,7-tridecadienyl-4(1H)-quinolone
Fenpiverinium
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
(1S,Z)-3-((2R)-6-hydroxy-2,5-dimethylnonylidene)-1-methyloctahydro-2H-quinolizin-1-ol
(7R,E)-8-((1S,Z)-1-hydroxy-1-methylhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol
C20H35NO3 (337.26168000000007)
C16:1-9-(L)-HSL
C20H35NO3 (337.26168000000007)
TETRABUTYLAMMONIUM METHANESULFONATE
C17H39NO3S (337.26505040000006)
8-Boc-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-8-aza-bicyclo[3.2.1]octane
C18H32BNO4 (337.24242620000007)
4-[[[2-(Diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid tert-butyl ester
C18H31N3O3 (337.23652960000004)
Safingol hydrochloride
C18H40ClNO2 (337.27474100000006)
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor D004791 - Enzyme Inhibitors
Decimemide
C19H31NO4 (337.22529660000004)
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
Cerebro
C20H35NOS (337.24392200000005)
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Erucate
A unsaturated fatty acid anion that is the conjugate base of erucic acid, formed by deprotonation of the carboxylic acid group.
(4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
(5Z,11Z,14Z)-8,9-Dihydroxyicosa-5,11,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11Z)-14,15-dihydroxyicosatrienoate
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,8Z,14Z)-11,12-dihydroxyicosatrienoate
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12-HPE(8,10,14)TrE(1-)
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of 12-HPE(8,10,14)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12(S)-HPE(5,8,10)TrE(1-)
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of 12(S)-HPE(5,8,10)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12(S)-HPE(8,10,14)TrE(1-)
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of 12(S)-HPE(8,10,14)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(8R,9E,11Z,14Z)-8-hydroperoxyicosatrienoate
C20H33O4- (337.23787180000005)
(8Z,11Z,14Z)-10-hydroperoxyicosatrienoate
C20H33O4- (337.23787180000005)
(8Z,12E,14Z)-11-hydroperoxyicosatrienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosa-5,8,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosa-5,8,11-trienoate
C20H33O4- (337.23787180000005)
(5Z,8R,9R,11Z,14Z)-8,9-dihydroxyicosa-5,11,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8S,9S,11Z,14Z)-8,9-dihydroxyicosa-5,11,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosa-5,8,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosa-5,8,11-trienoate
C20H33O4- (337.23787180000005)
(15S)-hydroperoxy-(8Z,11Z,13E)-eicosatrienoate
C20H33O4- (337.23787180000005)
Cetoleate
A straight-chain, monounsaturated fatty acid anion that is the conjugate base of cetoleic acid.
2-[[(9E,12E)-Octadeca-9,12-dienoyl]amino]acetic acid
C20H35NO3 (337.26168000000007)
(5S,12S)-dihydroxy-(6Z,8E,14Z)-icosatrienoate
C20H33O4- (337.23787180000005)
10,11-epoxy-12-hydroxy-(14Z,17Z)-eicosadienoate
C20H33O4- (337.23787180000005)
14,15-epoxy-12-hydroxy-(10E,17Z)-eicosadienoate
C20H33O4- (337.23787180000005)
N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexanamide
C20H35NO3 (337.26168000000007)
N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]butanamide
C20H35NO3 (337.26168000000007)
N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]acetamide
C20H35NO3 (337.26168000000007)
N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]propanamide
C20H35NO3 (337.26168000000007)
N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]pentanamide
C20H35NO3 (337.26168000000007)
(9Z,12Z)-N-(2-hydroxyethyl)nonadeca-9,12-dienamide
Fenpiverinium
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
(5Z,11Z,14Z)-8,9-dihydroxyicosatrienoate
A polyunsaturated fatty acid anion that is the conjugate base of (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosatrienoate
A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosatrienoate
A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosatrienoic acid; major species at pH 7.3.
10,11-dihydroleukotriene B4(1-)
An icosanoid anion that is the conjugate base of 10,11-dihydroleukotriene B4, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Docosenoate
A monounsaturated fatty acid anion that is the conjugate base of docosenoic acid, formed by deprotonation of the carboxylic acid group. Major species at pH 7.3.
(5Z,8S,9S,11Z,14Z)-8,9-dihydroxyicosatrienoate
A (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8S,9S,11Z,14Z)-8,9-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosatrienoate
A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosatrienoate
A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8R,9R,11Z,14Z)-8,9-dihydroxyicosatrienoate
A (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8R,9R,11Z,14Z)-8,9-dihydroxyicosatrienoic acid; major species at pH 7.3.
AcCa(12:3)
C19H31NO4 (337.22529660000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
(2s,3s,4r,5r)-2-[(2e,4e,6e)-deca-2,4,6-trien-2-yl]-4-methoxy-5-methyloxan-3-yl 2-aminoacetate
C19H31NO4 (337.22529660000004)
n-[3-(acetyloxy)hexadeca-11,15-dien-2-yl]ethanimidic acid
C20H35NO3 (337.26168000000007)
5-(1h-indol-2-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
(2s,3r,4s,5s)-2-[(2e,4e,6e)-deca-2,4,6-trien-2-yl]-4-methoxy-5-methyloxan-3-yl 2-aminoacetate
C19H31NO4 (337.22529660000004)
(2s,4as,5r,6r)-5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
n-[(2s,3r,11e)-3-(acetyloxy)hexadeca-11,15-dien-2-yl]ethanimidic acid
C20H35NO3 (337.26168000000007)
(2s,5r,6s,8ar)-5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-2-ol
n-[(2s,3r,7z)-3-(acetyloxy)hexadeca-7,15-dien-2-yl]ethanimidic acid
C20H35NO3 (337.26168000000007)
(2s,5r,6r,8ar)-5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-2-ol
5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-2-ol
2-hydroxy-13-(1-hydroxypropyl)-1h,4h,5h,6h,7h,9h,10h,11h,13h,16h,16ah-pyrido[2,1-d]1,5,9-triazacyclotridecane-8-carbaldehyde
C18H31N3O3 (337.23652960000004)
(2s,4as,5r,6r)-5-(1h-indol-2-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
4-[(1e)-3-({4-[(3-aminopropyl)amino]butyl}amino)prop-1-en-1-yl]-2,6-dimethoxyphenol
C18H31N3O3 (337.23652960000004)
n-[3-(acetyloxy)hexadeca-7,15-dien-2-yl]ethanimidic acid
C20H35NO3 (337.26168000000007)
(13s,16ar)-2-hydroxy-13-[(1s)-1-hydroxypropyl]-1h,4h,5h,6h,7h,9h,10h,11h,13h,16h,16ah-pyrido[2,1-d]1,5,9-triazacyclotridecane-8-carbaldehyde
C18H31N3O3 (337.23652960000004)